Skip to content
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Home
(current)
Diseases
Parkinson's Disease
Multiple Sclerosis and Related Disorders
Headache
Amyotrophic Lateral Sclerosis
Epilepsy
Sleep Disorders
Stroke
Neuromuscular Disorders
Movement Disorders
View all Diseases
Topics
Biology
Diagnostics
Trial Updates
Treatment
Prevention
Surgery
Imaging
Genetics
COVID-19
View all Topics
Conferences
ESOC 2022
AAN 2022
CONy 2022
AD/PD 2022
World Sleep 2022
ACTRIMS 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Natalizumab
1:28
Novel agents to control seizures & target epileptogenesis
Claude Steriade
• 24 Mar 2022
3:15
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with MS treated with DMTs
Virginia Meca-Lallana
• 28 Feb 2022
2:14
Autoreactive T-cell responses in multiple sclerosis: unanswered questions
Olivia Thomas
• 21 Oct 2021
6:29
Characterizing the autoantigen-specific T-cell repertoire in MS
Olivia Thomas
• 21 Oct 2021
7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico
• 30 Sep 2021
2:08
Discovering markers of disease progression in patients with MS treated with natalizumab
Charlotte Teunissen
• 6 Oct 2021
1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara
• 14 Oct 2021
6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara
• 14 Oct 2021
3:30
Long-term efficacy outcomes of natalizumab vs. fingolimod in highly active RRMS
Nikolaos Grigoriadis
• 20 Sep 2021
5:26
BBB permeability changes predict treatment response to alemtuzumab in RRMS
Maria Højberg Knudsen
• 1 Oct 2021
2:12
The future of biomarkers in MS: novel discoveries and defining protocols
Charlotte Teunissen
• 6 Oct 2021
9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì
• 22 Jun 2021
2:43
Benefits of SC natalizumab in MS
Bart Van Wijmeersch
• 23 Jun 2021
2:19
Enhancing convenience and flexibility with SC natalizumab for MS
Bart Van Wijmeersch
• 23 Jun 2021
3:26
NfL to monitor treatment effects in MS
Charlotte Teunissen
• 4 Jun 2021
4:28
Novel biomarkers to predict progression in MS
Charlotte Teunissen
• 4 Jun 2021
1
2
Next